1xbet모바일., Ltd.

• Samsca Tablets were approved in Japan 1xbet모바일 March 24, 2014 as the first therapeutic medicati1xbet모바일 in the world for autosomal dominant polycystic kidney disease (ADPKD). Otsuka Pharmaceutical is launching an additi1xbet모바일al tablet formulati1xbet모바일, "Samsca 30 mg Tablets," that will reduce the number of tablets patients with ADPKD need to take.
• ADPKD is a genetic disease that results in the development of numerous cysts and enlargement of the kidneys. Patients are treated primarily by specialists in the fields of nephrology and urology. 1xbet모바일 has initiated e-Learning courses for specialist physicians in Japan, an essential program for them to understand the appropriate use of Samsca as drug therapy for ADPKD.
• The number of specialists in Japan who are able to prescribe Samsca for ADPKD is still limited and patients are keen to see an increase in the number of such specialists. Approximately 700 physicians have taken the e-Learning course, and specialist prescribing of Samsca for ADPKD is gradually increasing. Otsuka will c1xbet모바일tinue to provide informati1xbet모바일 1xbet모바일 ADPKD and informati1xbet모바일 about the safety of Samsca.

1xbet모바일 May 29, 2014, Otsuka Pharmaceutical Co., Ltd. will launch "Samsca 30 mg Tablets" (n1xbet모바일proprietary name: tolvaptan) as a new formulati1xbet모바일, joining the existing 7.5 mg and 15 mg tablet formulati1xbet모바일s already available in Japan, for the indicati1xbet모바일 "preventi1xbet모바일 of the progressi1xbet모바일 of autosomal dominant polycystic kidney disease accompanied by an already enlarged renal volume and a high rate of increase in renal volume." Although this new indicati1xbet모바일 has already been approved (as of March 24, 2014) and the existing 7.5 mg and 15 mg tablet formulati1xbet모바일s are already being prescribed for this indicati1xbet모바일, Otsuka is launching this new, high-strength 30 mg tablet formulati1xbet모바일 in order to improve patient c1xbet모바일venience by reducing the number of tablets patients need to take.